Display options
Cite
Hartmann S, Brands RC, Küchler N, et al. Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer. Oncol Lett. 2015;10(2):1211-1217doi: 10.3892/ol.2015.3345.
Hartmann, S., Brands, R. C., Küchler, N., Fuchs, A., Linz, C., Kübler, A. C., & Müller-Richter, U. D. (2015). Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer. Oncology letters, 10(2), 1211-1217. https://doi.org/10.3892/ol.2015.3345
Hartmann, Stefan, et al. "Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer." Oncology letters vol. 10,2 (2015): 1211-1217. doi: https://doi.org/10.3892/ol.2015.3345
Hartmann S, Brands RC, Küchler N, Fuchs A, Linz C, Kübler AC, Müller-Richter UD. Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer. Oncol Lett. 2015 Aug;10(2):1211-1217. doi: 10.3892/ol.2015.3345. Epub 2015 Jun 09. PMID: 26622654; PMCID: PMC4509046.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2015 Aug;10(2):1211-1217. doi: 10.3892/ol.2015.3345. Epub 2015 Jun 09.

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer.

Oncology letters

Stefan Hartmann, Roman C Brands, Nora Küchler, Andreas Fuchs, Christian Linz, Alexander C Kübler, Urs D A Müller-Richter

Affiliations

  1. Department of Oral and Maxillofacial Plastic Surgery, University Hospital of Würzburg, Würzburg, Franconia D-97070, Germany.

PMID: 26622654 PMCID: PMC4509046 DOI: 10.3892/ol.2015.3345

Abstract

Melanoma-associated antigen (MAGE) has been identified in a variety of types of cancer. The expression of several MAGE subgroups is correlated with poor prognosis and chemotherapeutic resistance. One target of chemotherapeutic treatment in head and neck cancer is the epidermal growth factor receptor (EGFR). The efficacy of tyrosine kinase inhibitors (TKI) in the context of melanoma-associated antigens is discussed in the present study. Five human squamous cell carcinoma cell lines were treated with the EGFR TKIs, erlotinib and gefitinib. The efficacy of these agents was measured using a crystal violet assay. Furthermore, the expression levels of MAGE-A1, -A5, -A8, -A9, -A11 and -A12 were determined by reverse transcription-quantitative polymerase chain reaction. The association between TKI efficacy and MAGE-A expression was analyzed by linear regression. The cell lines revealed inhomogeneous expression patterns for the MAGE-A subgroups. Four of the five cell lines demonstrated a good response to erlotinib and gefitinib. However, treatment with erlotinib induced better results than those of gefitinib, and revealed a concentration-dependent effect. The expression of MAGE-A5 and -A11 were significantly correlated with lower efficacy of erlotinib and gefitinib. By contrast, MAGE-A12 was associated with a superior response to these two drugs. One cell line, which expressed all investigated MAGE-A subgroups, was entirely resistant to the two TKIs. These results revealed a notable correlation between MAGE-A5 and -A11 and lower efficacy of EGFR TKIs. Pretreatment analysis of MAGE-A status may therefore aid improvement of chemoprevention using erlotinib and gefitinib in head and neck cancer.

Keywords: epidermal growth factor receptor; erlotinib; gefitinib; melanoma-associated antigen-A; tumor antigen

References

  1. J Biol Chem. 2013 Aug 23;288(34):24809-24 - PubMed
  2. J Immunol. 2007 Mar 1;178(5):2617-21 - PubMed
  3. World J Clin Oncol. 2014 Oct 10;5(4):646-59 - PubMed
  4. Int J Oncol. 2012 Sep;41(3):1085-93 - PubMed
  5. J Exp Ther Oncol. 2013;10(3):209-14 - PubMed
  6. ORL J Otorhinolaryngol Relat Spec. 2004;66(6):332-40 - PubMed
  7. Clin Oral Investig. 2014 Jan;18(1):189-97 - PubMed
  8. Cancer Res. 2007 Oct 15;67(20):9954-62 - PubMed
  9. Pathol Res Pract. 2013 Nov;209(11):721-6 - PubMed
  10. Clin Cancer Res. 2013 Mar 1;19(5):1244-56 - PubMed
  11. Int J Cancer. 2014 Sep 1;135(5):1142-52 - PubMed
  12. J Craniomaxillofac Surg. 2013 Oct;41(7):623-9 - PubMed
  13. Oral Oncol. 2008 Jul;44(7):628-33 - PubMed
  14. Head Neck. 2003 Jun;25(6):457-63 - PubMed
  15. Sci Transl Med. 2011 Sep 7;3(99):99ra86 - PubMed
  16. J Exp Med. 1998 Apr 20;187(8):1163-7 - PubMed
  17. J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94 - PubMed
  18. Clin Oral Investig. 2011 Jun;15(3):315-20 - PubMed
  19. Cancer Invest. 2012 Aug;30(7):495-502 - PubMed
  20. J Craniomaxillofac Surg. 2014 Oct;42(7):1322-8 - PubMed
  21. Arch Med Res. 2014 Jan;45(1):44-51 - PubMed
  22. Cancer Immun. 2004 Jan 23;4:1 - PubMed
  23. Clin Cancer Res. 2014 Jun 15;20(12):3289-98 - PubMed
  24. Nat Rev Cancer. 2005 Aug;5(8):615-25 - PubMed
  25. Dis Markers. 2008;24(1):27-32 - PubMed
  26. Cancer Res. 1989 Sep 15;49(18):5167-75 - PubMed
  27. Ann Surg Oncol. 2014 Dec;21(13):4263-9 - PubMed
  28. J Clin Oncol. 2007 Jun 1;25(16):2164-70 - PubMed
  29. Clin Cancer Res. 2011 Sep 15;17(18):5935-44 - PubMed
  30. Mol Cell. 2010 Sep 24;39(6):963-74 - PubMed
  31. Cell. 2007 Nov 30;131(5):1018 - PubMed
  32. J Clin Oncol. 2013 Apr 10;31(11):1415-21 - PubMed

Publication Types